Quantcast
Last updated on April 23, 2014 at 13:36 EDT

Latest Joseph Rogers Stories

2013-09-23 12:26:29

The award recognizes Rogers' extraordinary leadership and advocacy to advance the recovery movement of individuals with mental health conditions. PHILADELPHIA, Sept. 23, 2013 /PRNewswire-USNewswire/ -- On Sept. 25, the federal Substance Abuse and Mental Health Services Administration (SAMHSA) will present Joseph Rogers with its 2013 Lifetime Achievement Voice Award. The event will take place at Paramount Theater at Paramount Studios, 5555 Melrose Ave., Hollywood, California, at 7...

2012-08-28 06:28:51

MENLO PARK, Calif., Aug. 28, 2012 /PRNewswire/ -- Joseph Rogers, Ph.D., has joined SRI's Biosciences Division as executive director of a new Health Sciences Section that brings together researchers from SRI's Center for Health Sciences, led by Gary Swan, Ph.D., with SRI's Center for Neuroscience and Metabolic Diseases, led by Thomas Kilduff, Ph.D. This combination offers SRI clients and partners more integrated bench-to-bedside capabilities in areas such as addiction, alcoholism, Alzheimer's...

2010-05-21 08:43:00

PHILADELPHIA, May 21 /PRNewswire-USNewswire/ -- Joseph Rogers, Chief Advocacy Officer of the Mental Health Association of Southeastern Pennsylvania (MHASP), will receive the 2010 Lifetime Achievement Award from Eli Lilly and Company on May 22 at 2 p.m. at the Roosevelt Hotel, 123 Baronne Street, New Orleans, Louisiana, in the Conti Room. The award includes $15,000 for the non-profit organization of the honoree's choice. Rogers overcame psychiatric hospitalizations and homelessness to...

2009-11-17 07:00:00

PLEASANTON, Calif., Nov. 17 /PRNewswire-FirstCall/ --Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said that data released today from the Destination Therapy (DT) pivotal trial for the HeartMate II left ventricular assist system (LVAS) demonstrate that the device achieved statistically superior results over the HeartMate XVE, including survival at two years while remaining free from...

2005-11-14 13:16:12

DALLAS. "“ Pumps implanted into the chest to maintain circulation can significantly extend the lives of the sickest patients in end-stage heart failure who are not candidates for heart transplantation, according to the results of a clinical trial led by Duke University Medical Center cardiologists. The pumps, known as left ventricular assistant devices (LVADs), are employed when the heart's left ventricle "“ the chamber of the heart that pumps blood throughout the body "“...